Bluebird bio Inc., which nine years ago was worth nearly as much as the airline JetBlue, said it's now looking for enough ...
The clinical stage biopharmaceutical company is developing inhaled drug delivery devices. Transpire Bio expands headquarters ...
The European Commission is asking biopharma and manufacturing companies about their reaction to Novo ...
On Oct. 15, Modifi Bio, a Yale-based biotech company, closed an acquisition deal with Merck, an American pharmaceutical ...
BridgeBio Pharma’s acoramidis shows improved survival data, boosting approval chances. Read why BBIO stock could see gains if ...
Shares of Avidity Biosciences surged to a record high Wednesday after the company showed its hand in the cardiovascular space ...
The primary contractor for the project will be appointed next week. Keturah completes infrastructure work on Dubai’s first ...
Next-generation metagenomic sequencing test developed at UCSF proves its effectiveness in quickly diagnosing almost any kind ...
The company has discontinued the Phase I/II trial of its only clinical candidate due to a potential “unfavourable ...
Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of ...
Sensei Biotherapeutics is laying off 46% of its workforce as the cancer-focused biotech looks to preserve cash to take its ...
SOMERVILLE, Mass.--(BUSINESS WIRE)--bluebird bio, Inc. (NASDAQ: BLUE) ("bluebird bio" or the "Company") today reported third quarter results and business highlights for the quarter ended September ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback